Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LCTX vs ACRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: LCTX 4 – 1 ACRS (1 Tie) Matrix Metrics: LCTX 6 – 4 ACRS

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin), whereas ACRS carries 45.2/100 (HOLD) at $3.44 (N/M Forward P/E, -1412.4% operating margin).

  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs ACRS
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.44
-1.71% 1D
Market Cap $555.1M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.42β · 69% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 42.0 Fund 57.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $3.82 · SMA50: $4.21

6-Pillar Scorecard Institutional Category Breakdown (LCTX 4 – 1 ACRS)

Columns: Metric · LCTX · ACRS
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 15.9x 86.7x
2. Growth & Scale ACRS
Revenue Growth (YoY) -61.0% -55.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $6.4M
Market Cap $207.4M $555.1M
3. Profitability & Quality LCTX
Gross Margin -95.0% N/A
Operating Margin -280.3% -1412.4%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -55.5%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $1.11 Book/Sh · -55.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LCTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 0.0% (<1st %ile) 60.7% (<1st %ile)
Put/Call OI Skew N/A 40.79x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (6) vs ACRS (4)
Institutional Metric LCTX ACRS Criterion Row Edge
Market Capitalization
Scale
$207.4M $555.1M Larger Scale ACRS
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% -55.1% Higher Growth ACRS
Operating Margin (TTM)
Profitability
-280.3% -1412.4% Higher Margin LCTX
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -55.5% Higher ROE LCTX
52-Week Range Position
Momentum
0% ($1–$2) 26% ($2–$7) Stronger Trend ACRS
Beta / 30D Volatility
Risk Regime
1.39β · 79% Vol 1.42β · 69% Vol Lower Realized Risk ACRS
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $6.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 15.9x EV/Rev N/M PEG · 86.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$75M ($1.11 Book/Sh · -55.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACRS +11.45 pp
LCTX: -21.63% · ACRS: -10.18%
3M Horizon LCTX +16.3 pp
LCTX: -29.18% · ACRS: -45.48%
6M Horizon ACRS +16.73 pp
LCTX: -40.62% · ACRS: -23.89%
1Y Horizon ACRS +94.7 pp
LCTX: -54.86% · ACRS: +39.84%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue ACRS Revenue LCTX Op. Margin ACRS Op. Margin Margin Leader
FY2018 $0M $10M -837.9% -1378.3% LCTX
FY2019 $0M $0M -1106.0% -2627.3% LCTX
FY2020 $0M $10M -1448.4% -785.4% ACRS
FY2021 $0M $10M -1133.6% -1327.1% LCTX
FY2022 $10M $30M -153.2% -302.0% LCTX
FY2023 $10M $30M -276.5% -311.6% LCTX
FY2024 $10M $20M -226.1% -758.2% LCTX
FY2025 $10M $10M -251.6% -975.9% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 60.7%
IV Percentile <1st %ile
Put/Call OI Skew 40.79x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $555.1M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs ACRS Key Questions & Quantitative Answers

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin), whereas ACRS carries 45.2/100 (HOLD) at $3.44 (N/M Forward P/E, -1412.4% operating margin). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACRS leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while ACRS shifted +0.0%. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 86.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus ACRS (-55.5% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 40.79x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.